Molecular Weight(MW): 310.41
Divalproex Sodium, consisting of a compound of sodium valproate and valproic acid in a 1:1 molar relationship in an enteric coated form, is a HDAC inhibitor, used in the treatment for epilepsy.
1 Customer Review
Divalproex sodium increases the level of acetylated histone H3 level in ataxin-3-transfected HEK293 cells. Normal (15CAG) or expanded (77CAG) ataxin-3-transfected cells were treated with divalproex sodium (Selleck chemical, 0.3 mmol/L in DMSO, (+)) or with DMSO alone (−) 48 h after transfection. The cells were treated with divalproex sodium or DMSO over 6, 12, and 24 h. The Western blot was probed with antiacetylated histone H3, antihistone H3, and antiataxin-3. Antibodies include antihistone H3 and antiataxin-3 are used as controls. The x-axis shows the different treatment group. The y-axis represents the acetylated histone H3 values normalized to histone H3. Error bars represent the standard error of the mean. Data represent three independent experiments (n = 3). The data with a normal distribution were analyzed with Student’s t-test. *P < 0.05
CNS Neurosci Ther, 2018, 24(5):404-411. Divalproex Sodium purchased from Selleck.
Purity & Quality Control
Choose Selective HDAC Inhibitors
|Description||Divalproex Sodium, consisting of a compound of sodium valproate and valproic acid in a 1:1 molar relationship in an enteric coated form, is a HDAC inhibitor, used in the treatment for epilepsy.|
Divalproex sodium enhances IM-induced cell growth inhibition, apoptosis and cell cycle arrest in K562-S and K562-G cells. Divalproex sodium enhances the inhibitory effects of IM on SIRT1 expression in K562-S and K562-G cells. Divalproex sodium enhances the effect of IM on apoptosis in K562-G cells partly through SIRT1.  Divalproex (500 mg/kg) significantly increases dopamine (DA) and acetylcholine (ACh) efflux in the rat hippocampus, and DA, but not ACh, efflux in the rat medial prefrontal cortex (mPFC), whereas a lower dose of Divalproex, 50 mg/kg, has no effect on DA or ACh in either region. Divalproex (50 mg/kg) combined with the atypical APDs Olanzapine (1.0 mg/kg) or Aripiprazole (0.3 mg/kg) significantly potentiates the effect of both antipsychotic drugs (APDs) on DA, but not ACh efflux in the HIP and mPFC. 
|In vitro||DMSO||62 mg/mL (199.73 mM)|
|Water||62 mg/mL (199.73 mM)|
|Ethanol||62 mg/mL (199.73 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT01170325||Withdrawn||Autism|Autism Spectrum Disorders||National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)||June 30 2010||Phase 2|
|NCT02166229||Withdrawn||Scleroderma|Systemic Sclerosis||Yale University||June 2014||Phase 1|Phase 2|
|NCT02094651||Withdrawn||Autism||Boston Children’s Hospital|University of Louisville||April 2014||Phase 2|
|NCT01898676||Unknown status||Epilepsy||Vince & Associates Clinical Research Inc.|Food and Drug Administration (FDA)||July 2013||Phase 1|
|NCT01575561||Completed||Bipolar I Disorder||Sunovion||June 2012||Phase 3|
|NCT01358357||Completed||Bipolar I Disorder||Sunovion||June 2011||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.